Senolytic combination therapy targeting senescent cells
Aging is a primary risk factor for disease progression in multiple sclerosis (MS). Because of this, treatments that can reduce the consequences of molecular aging, like senescence, have been proposed as a strategy to address …
Researchers treated female mice with fatty liver disease (MASLD) using senolytic drugs—compounds that eliminate senescent (aged) cells—and found pregnancy rates improved, particularly through reduced aging and inflammation in the ovaries. However, the treatment had limited …
Researchers tested whether dasatinib and quercetin—drugs that eliminate senescent (aging) cells—could prevent bone loss in the jaw. The treatment worked in naturally aged mice but failed in a gum disease model, suggesting senolytic benefits may …
Researchers found that two drugs given together—dasatinib and quercetin—slowed age-related disc degeneration in genetically susceptible mice by clearing senescent (aged) cells. The treatment worked in mice's discs but hasn't been tested in humans yet, and …
Researchers found that a protein called IL33 prevents placental aging; when it's missing, the placenta deteriorates through a chain reaction involving lactate buildup and broken autophagy (cellular cleanup). Senescence-targeting drugs like metformin and dasatinib+quercetin restored …
Despite optimal lipid-lowering treatment, numerous older adults with atherosclerotic cardiovascular disease continue to experience progression driven by inflammation, referred to as residual inflammatory risk. Cellular senescence and the senescence-associated secretory phenotype (SASP) significantly contribute to …